ASS1 and neoplasm: Preclinical studies have demonstrated suppression of both de novo pyrimidine synthesis and the pyrimidine salvage pathway with the combination ADI‐PEG20 and pemetrexed (Allen et al., 2013), countering the enhanced pyrimidine synthesis and proliferation of ASS1‐deficient tumours (Rabinovich et al., 2015).